

Biosafety Permit Application

**Presentation to the
Cambridge Biosafety
Committee**




































**Greg Hoffman
May 16, 2019.**

Sana Biotechnology - Introduction

- Sana was founded in 2018.
- Sana has labs and offices in Seattle, San Francisco, and Cambridge.
- Sana is a privately held, early stage biotechnology company that aims to leverage recent scientific advances that make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.
- Sana currently has **~100** employees. ~55 employees are located in Cambridge.
- Sana currently operates at space in SmartLabs on Erie St and is building out future lab/office space at 300 Technology Square with a move in date of later this year.
- Sana has plans to conduct rDNA research at both locations.

Sana Biotechnology – Management and Scientific Team

Experienced team with expertise in gene engineering, cell therapy, and manufacturing sciences

Leadership Team		
Cambridge Site Head	Steve Harr, M.D.	Chief Executive Officer  Morgan Stanley
	Hans Bishop	Executive Chair  Dendreon 
	Sunil Agarwal, M.D.	Chief Development Officer  ultragenix 
	Chad Cowan, PhD	Chief Scientific Officer  CRISPR 
	Andy May D.Phil	Chief Technology Officer  Chan Zuckerberg Initiative 
	Sonja Schrepfer, M.D., PhD	SVP, Research   
	Robin Andrulevich	Chief People Officer  Madrigal 
	Nate Hardy	Chief Financial Officer  AMGEN 
	Christian Hordo	Chief Business Officer  Genentech 
	Jim MacDonald, J.D.	General Counsel  xPERI 
Board of Directors		
Hans Bishop (Exec. Chair)		 Dendreon 
Noubar Afeyan, PhD		
Tom Daniel, M.D.		 Celgene 
Steve Harr, M.D.		 Morgan Stanley
Steve Knight, M.D.		
Richard Mulligan, PhD		 
Bob Nelsen		
Don Payan, M.D.		 UCSF 
Geoffrey von Maltzahn, PhD		
Pat Yang, PhD		 Genentech 

Research Platform and Corporate Mission

Sana's goal is to create the pre-eminent company utilizing engineered cells as medicines

Sana envision to pioneer the future of medicine using in vivo and ex vivo cell engineering to cure disease

